Toronto, Ontario – May 16, 2013, Theralase Technologies Inc. (TSXV: TLT)
(“Theralase”) announced today that its researchers have discovered a
significant new mechanism of action for a new class of Photo Dynamic Compounds
(PDCs), that have been custom designed to destroy cancer cells when activated
by a proprietary light source.
The preclinical
study, conducted by Theralase scientists and their colleagues at University
Health Network’s Princess Margaret Cancer Centre, was presented on May 15, at
the Laser World of Photonics conference held in Munich, Germany.
In previous
preclinical studies, Theralase’s PDCs have been proven to be promising anti-cancer
agents in various cancer models. Their efficacy involved a number of critical
cellular processes, including DNA damage and programmed cell death. All PDCs
were thought to work primarily by oxygen-dependent mechanisms, ultimately
causing cell death in the presence of highly reactive oxygen. In this study;
however, scientists established that a new class of Theralase PDCs have an
additional “oxygen independent” mechanism of action, which would increase
efficacy in the destruction of more clinically aggressive tumours.
The
research lead by Dr. Lothar Lilge, Senior Scientist, Ontario Cancer Institute, Princess
Margaret Cancer Centre and Dr. Arkady Mandel, Chief Scientific Officer, Theralase
has shown that specific metal-based PDCs when tested for effectiveness of
cancer destruction in a low oxygen environment were proven to be highly
effective in the destruction of human brain cancer cells in-vitro, thus activating this newly discovered pathway. Additionally
using this pathway, Theralase scientists confirmed in a preclinical model a complete response rate and the
destruction of subcutaneous (under the skin) colon cancer tumours in mice,
which were treated with Theralase’s anti-cancer PDC technology. On follow-up, the
initial complete response was maintained in two-thirds of the animals for over
1 year without recurrence.
Roger
Dumoulin-White, President and CEO of Theralase Technologies Inc. stated,
“Recognition of our world class anti-cancer research at the Munich conference
is another testament to the cutting edge research our scientists are conducting
in this field. Our findings would strongly suggest that Theralase’s PDCs oxygen
independent potency would significantly enhance our ability to destroy cancer
cells. Tumours in a low oxygen environment have been extremely challenging because
this lack of oxygen renders solid tumours much more resistant to therapeutic
interventions. Many traditional therapeutic agents, conducted on
poorly oxygenated solid core tumours, including any currently FDA approved PDCs, are susceptible to a
“self-limiting” activity; whereby, below a critical threshold oxygenation level,
their efficacy is progressively reduced resulting in minimal to no cancer cell
destruction. This new class of Theralase PDCs are not susceptible to this “self-limiting”
activity and as a result maintain their efficacy even in extremely low oxygenated
cancerous tumours, such as breast and prostate cancer. As a result, Theralase is extremely
excited about the latest research and what it means in the field of cancer
destruction. Theralase is committed to the early commercialization of its patented
light activated Photo Dynamic Compounds in the areas of anti-cancer and
anti-bacterial applications to generate substantial revenues for the Company
and hence dramatically increase shareholder value.”
About Theralase Technologies Inc.
Theralase
Technologies Inc., founded in 1995, designs, develops, manufactures and markets
patented, superpulsed laser technology utilized in biostimulation and
biodestruction applications. Theralase technology is safe and effective in
treating pain, inflammation and for tissue regeneration of neural muscular
skeletal conditions Theralase is currently developing patented Photo Dynamic
Compounds (PDCs) that are able to target and destroy cancers, bacteria and
viruses when light activated by Theralase’s proprietary laser technology.
For
further information please visit www.theralase.com
, regulatory filings may be viewed by visiting www.sedar.com.
This press release
contains forward-looking statements, which reflect the Company's current
expectations regarding future events. The forward-looking statements involve
risks and uncertainties. Actual results could differ materially from those
projected herein. The Company disclaims any obligation to update these
forward-looking statements.
Neither TSX Venture
Exchange nor its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchanges) accepts responsibility for the adequacy
or accuracy of this release.
For More Information, please contact:
Roger Dumoulin-White,
President & CEO
416-699-LASE (5273) ext. 225
Kristina Hachey
Chief Financial Officer
416-699-LASE (5273) ext. 224
Greg Bewsh
Director of Investor Relations
416-699-LASE (5273) ext. 258
Arkady
Mandel
Chief
Scientific Officer
416-699-LASE
(5273) ext. 260
Sound therapy is a blend of different sound formulas which are produced by many sound emitting tools which can heal diseases as common as cold to as difficult to cure diseases like cancer, Alzheimer’s, Parkinson’s etc.
ReplyDeleteSound therapy is effective in Cancer healing effectively and rapidly. It can also assist in healing if the patient is under any medical treatment for Acute Sinusitis.